

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

东曜药业

TOT BIOPHARM International Company Limited

東曜藥業股份有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 1875)

CHANGE OF DIRECTORS AND CHANGE OF COMPOSITION OF BOARD COMMITTEES

RESIGNATION OF NON-EXECUTIVE DIRECTOR

The board of directors (the “**Board**”) of TOT BIOPHARM International Company Limited (the “**Company**”) hereby announces that Mr. Qiu, Yu Min (裘育敏先生) (“**Mr. Qiu**”) has resigned from his roles as a non-executive director of the Company, the chairperson of the Remuneration Committee and a member of each of the Audit and Connected Transactions Review Committee and the Strategy and ESG Committee, all with effect from 12 August 2023, due to his other business engagements which require more of his dedication. Mr. Qiu will also resign from his position as a director of TOT BIOPHARM Co., Ltd. (東曜藥業有限公司) (“**TOT Suzhou**”), a wholly-owned subsidiary of the Company, in due course.

Mr. Qiu has confirmed that, as at the date of this announcement, he has no disagreement with the Board and he is not aware of any matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited (“**Hong Kong Stock Exchange**”).

The Board would like to express its sincere gratitude to Mr. Qiu for his contribution to the Company during his term of office.

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The Board is pleased to announce that Dr. Liu, Weidong (劉衛東博士) (“**Dr. Liu, Weidong**”) has been appointed as a non-executive director of the Company, the chairperson of the Remuneration Committee and a member of each of the Audit and Connected Transactions Review Committee and the Strategy and ESG Committee, all with effect from 12 August 2023. Dr. Liu, Weidong will also be appointed as a director of TOT Suzhou in due course.

Dr. Liu, Weidong, aged 55, possesses extensive experience in pharmaceutical process research and development as well as CMC (chemistry, manufacturing and controls) management. He obtained a bachelor's degree and a master's degree in chemistry from Peking University (北京大學) in China in 1989 and 1994, respectively, and obtained a Ph.D. in organic chemistry from the University of Pittsburgh in the United States in 2000. He worked at Array BioPharma Inc. (formerly NASDAQ: ARRY; now part of Pfizer Inc. (New York Stock Exchange: PFE)) from October 2001 to May 2015 with his last position as principal research investigator of process chemistry. He then worked at Avista Pharma Solutions (now part of Cambrex Corporation (formerly New York Stock Exchange: CBM)) from June 2015 to February 2016 as director of process chemistry, and at Changzhou STA Pharmaceutical R&D Co., Ltd. (常州合全新藥研發有限公司) (a subsidiary of WuXi AppTec Co., Ltd. (無錫藥明康德新藥開發股份有限公司) (Hong Kong Stock Exchange: 2359; Shanghai Stock Exchange: 603259)) from March 2016 to April 2017 as executive director of process research and development.

Dr. Liu, Weidong joined Vivo Capital LLC, a substantial shareholder of the Company, in August 2017 and is currently serving as managing director. He served as a director of Genetron Holdings Limited (NASDAQ: GTH) between November 2019 and June 2021.

Dr. Liu, Weidong's directorship is subject to retirement by rotation and re-election in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Company's articles of association. Dr. Liu, Weidong has signed a letter of appointment with the Company for a term of three years commencing on 12 August 2023, under which he is entitled to a remuneration of HK\$1 annually, determined by the Board having regard to the recommendation of the Remuneration Committee and with reference to his contributions, experience and relevant duties and responsibilities within the Company.

Save as disclosed above, as at the date of this announcement, Dr. Liu, Weidong (i) does not have any relationship with any director, senior management, substantial shareholder or controlling shareholder (as defined in the Listing Rules) of the Company, except that both Dr. Liu, Weidong and Mr. Fu, Shan (another non-executive director of the Company) represent Vivo Capital LLC on the Board; (ii) does not hold any other positions with the Company and/or its subsidiaries; (iii) has not held any other directorship in any public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; and (iv) does not have, and is not deemed to have, any interests in any shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Dr. Liu, Weidong has confirmed that, save as disclosed above, there is no other information required to be brought to the attention of the shareholders of the Company pursuant to Rule 13.51(2) of the Listing Rules in relation to his appointment as a non-executive director of the Company.

The Board would like to express its warm welcome to Dr. Liu, Weidong for joining the Board.

By Order of the Board
TOT BIOPHARM International Company Limited
Dr. Liu, Jun
Chief Executive Officer and Executive Director

Hong Kong, 11 August 2023

As at the date of this announcement, the executive director of the Company is Dr. Liu, Jun; the non-executive directors of the Company are Mr. Fu, Shan, Ms. Yeh-Huang, Chun-Ying and Mr. Qiu, Yu Min; and the independent non-executive directors of the Company are Ms. Hu, Lan, Mr. Chang, Hong-Jen and Dr. Wang, De Qian.